A detailed history of Principal Financial Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 289,965 shares of RCUS stock, worth $4.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
289,965
Previous 332,814 12.87%
Holding current value
$4.25 Million
Previous $6.36 Million 13.88%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$14.83 - $20.18 $635,450 - $864,692
-42,849 Reduced 12.87%
289,965 $5.47 Million
Q4 2023

Feb 07, 2024

BUY
$13.43 - $19.63 $45,285 - $66,192
3,372 Added 1.02%
332,814 $6.36 Million
Q3 2023

Nov 02, 2023

BUY
$17.62 - $23.54 $23,117 - $30,884
1,312 Added 0.4%
329,442 $5.91 Million
Q2 2023

Aug 07, 2023

BUY
$16.97 - $22.03 $57,528 - $74,681
3,390 Added 1.04%
328,130 $6.66 Million
Q1 2023

May 09, 2023

SELL
$15.96 - $23.15 $68,101 - $98,781
-4,267 Reduced 1.3%
324,740 $5.92 Million
Q4 2022

Feb 09, 2023

SELL
$19.7 - $35.71 $240,320 - $435,626
-12,199 Reduced 3.58%
329,007 $6.8 Million
Q3 2022

Nov 09, 2022

BUY
$23.23 - $30.07 $219,035 - $283,530
9,429 Added 2.84%
341,206 $8.93 Million
Q2 2022

Aug 10, 2022

BUY
$17.23 - $37.73 $5.57 Million - $12.2 Million
323,465 Added 3891.54%
331,777 $8.41 Million
Q1 2022

May 09, 2022

SELL
$28.92 - $41.83 $7,750 - $11,210
-268 Reduced 3.12%
8,312 $262,000
Q4 2021

Feb 09, 2022

SELL
$31.38 - $48.47 $172,558 - $266,536
-5,499 Reduced 39.06%
8,580 $347,000
Q3 2021

Nov 09, 2021

SELL
$26.93 - $37.68 $61,481 - $86,023
-2,283 Reduced 13.95%
14,079 $491,000
Q2 2021

Aug 10, 2021

SELL
$22.75 - $35.77 $160,433 - $252,250
-7,052 Reduced 30.12%
16,362 $449,000
Q1 2021

May 10, 2021

SELL
$26.16 - $41.39 $17,422 - $27,565
-666 Reduced 2.77%
23,414 $657,000
Q4 2020

Feb 08, 2021

BUY
$17.0 - $32.36 $409,360 - $779,228
24,080 New
24,080 $625,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.06B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.